Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03267732 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
A Phase 1 study of Healthy Adult Subjects, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03267732 is a Phase 1 study of Healthy Adult Subjects that has completed, run by Eli Lilly and Company. The registered enrollment target is 24 participants, below the 36-participant average among 3 other Healthy Adult Subjects trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03267732, a Phase 1 study of Healthy Adult Subjects, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the pharmacokinetics of single and multiple doses of pegilodecakin in healthy participants.
Conditions Studied
Interventions
- BIOLOGICAL Pegilodecakin
Study Locations (1)
Texas
- PPD Development - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-09-05 |
| Est. Completion | 2017-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03267732
The ClinicalTrials.gov registry entry for NCT03267732 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36-participant average among 3 other Healthy Adult Subjects trials with a reported enrollment target (33% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Adult Subjects appearing as the primary indexed condition, and to 1 intervention - of which Pegilodecakin is the first listed.
NCT03267732 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03267732 about?
NCT03267732 is a clinical study titled "A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)". To evaluate the pharmacokinetics of single and multiple doses of pegilodecakin in healthy participants.
What is the current status of trial NCT03267732?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-09-05. Estimated completion is 2017-10-30.
What conditions does trial NCT03267732 study?
This clinical trial studies the following conditions: Healthy Adult Subjects.
What interventions are being tested in trial NCT03267732?
The interventions under investigation include: Pegilodecakin (BIOLOGICAL).
Who is sponsoring clinical trial NCT03267732?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03267732 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adult Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.